InterMune files pirfenidone for pulmonary fibrosis in US on mixed data
This article was originally published in Scrip
InterMune has filed its lead development candidate, pirfenidone, with the US FDA for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.